Onglyza

[Anonymous]

How well will BMS do selling 2 drugs that do the same thing. Bydureon

 

[Anonymous]

Bydureon is not a good drug. Yes, once a week is a benefit, however, it is far to complicated and time consuming to have huge sales.

 

[Anonymous]

Bydureon is not a good drug. Yes, once a week is a benefit, however, it is far to complicated and time consuming to have huge sales.

I agree with OP that it will be interesting to see how the company positions the use of Ong vs. Byd. However, I completely disagree with poster #2. I sell Byd (for now at least) and I can tell you that my providers have a grat deal of interest in the class, love the idea of once weekly and are seeing very good results with this drug. I believe the increased effort behind Byd that will take place soon are exactly what is needed at this time for Byd to reach its potential. I hope we are kept on board to sell with you, but even if not, dont let the novo reps or others with an axe to grind, sell you the lie that Byd is not a good drug.

 

[Anonymous]

Come on guys/gals it's pretty easy. If you need a slight decrease in a1c reduction you go dpp4 if you have a patient that's struggling higher than 8 on the a1c you have Bydureon . Patient profiling is key here.

 

[Anonymous]

Patients need to be on both and Abilify for their head issues.

 

[Anonymous]

Come on guys/gals it's pretty easy. If you need a slight decrease in a1c reduction you go dpp4 if you have a patient that's struggling higher than 8 on the a1c you have Bydureon . Patient profiling is key here.

What kind of managed care coverage does Bydureon have

 

[Anonymous]

Bydureon is not a good drug. Yes, once a week is a benefit, however, it is far to complicated and time consuming to have huge sales.

Agreed and why give BMS Bydureon and not Byetta. Seems like BMS REPS WILL BE TRYING TO CONVERT BYETTA TO BYDUREON AND AMYLIN REPS WILL BE GLAD NO MATTER WHICH ONE IS WRITTEN. CONFLICT BREWING

 

[Anonymous]

What kind of managed care coverage does Bydureon have

Very,very little. Much better wity Byetta.

 

[Anonymous]

Very,very little. Much better wity Byetta.

That's not true at all! Byetta does have better coverage with Medicare and Medicaid, but for being a new launch, Bydureon has lowest branded coverage on many commercial plans 4-7 months earlier than industry averages. The plans include Caremark/CVS, Express Scripts, Medco--and some BCBS plans have already gone Tier 2.

Hopefully the $10 copay cards that have been used with Onglyza are implemented quickly for Bydureon!

 

[Anonymous]

Agreed and why give BMS Bydureon and not Byetta. Seems like BMS REPS WILL BE TRYING TO CONVERT BYETTA TO BYDUREON AND AMYLIN REPS WILL BE GLAD NO MATTER WHICH ONE IS WRITTEN. CONFLICT BREWING

This is going to be a major problem.

 

[Anonymous]

That's not true at all! Byetta does have better coverage with Medicare and Medicaid, but for being a new launch, Bydureon has lowest branded coverage on many commercial plans 4-7 months earlier than industry averages. The plans include Caremark/CVS, Express Scripts, Medco--and some BCBS plans have already gone Tier 2.

Hopefully the $10 copay cards that have been used with Onglyza are implemented quickly for Bydureon!

Coverage for Onglyza is not great either, 3 years post launch. Formulary coverage comes and goes, docs get frustarted when they Rx and it gets kicked back so they don't try to Rx again.

Copay cards are not being used as one would expect. They are left at physician's office and pharmacy and usage is riduculously low.

 

[Anonymous]

Agreed and why give BMS Bydureon and not Byetta. Seems like BMS REPS WILL BE TRYING TO CONVERT BYETTA TO BYDUREON AND AMYLIN REPS WILL BE GLAD NO MATTER WHICH ONE IS WRITTEN. CONFLICT BREWING

This will be a major problem because Amylin does not give a hoot which drug is written and the poor BMS reps will be fighting to get this shit drug Bydureon written with its no managed care and complicated setup w/o having the ability to promote Byetta

 

[Anonymous]

You couldn't sell Onglyza when you had a ZERO copayment card! Januvia will continue to rock while the BMS diabetes franchise will wither.

 

[Anonymous]

This will be a major problem because Amylin does not give a hoot which drug is written and the poor BMS reps will be fighting to get this shit drug Bydureon written with its no managed care and complicated setup w/o having the ability to promote Byetta

Is this true? If so, we have a problem which has no resolve

 

[Anonymous]

Don't worry Richard has a plan